Niraparib
- Generic Name
- Niraparib
- Brand Names
- Zejula
- Drug Type
- Small Molecule
- Chemical Formula
- C19H20N4O
- CAS Number
- 1038915-60-4
- Unique Ingredient Identifier
- HMC2H89N35
- Background
Niraparib is an orally active poly (ADP-ribose) polymerase (PARP) inhibitor. By blocking the enzymes responsible for DNA repair, niraparib induces cytotoxicity in cancer cells. Niraparib is selective towards PARP-1 and PARP-2. First approved by the FDA on March 27, 2017, niraparib is used to treat epithelial ovarian, fallopian tube, or primary peritoneal can...
- Indication
Niraparib is indicated for the maintenance treatment of adult patients with advanced or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy.
...
- Associated Conditions
- Advanced Epithelial Ovarian Cancer, Advanced Primary Peritoneal Carcinoma, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Recurrent Epithelial Ovarian Cancer, Recurrent Fallopian Tube Cancer, Recurrent Primary Peritoneal Cancer, Advanced Fallopian Tubes Cancer
- Associated Therapies
- Maintenance therapy
A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Anticancer Activity of GSK4524101 Alone or With Niraparib in Participants With Solid Tumors
- First Posted Date
- 2023-10-11
- Last Posted Date
- 2024-04-11
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 135
- Registration Number
- NCT06077877
- Locations
- 🇨🇦
GSK Investigational Site, Toronto, Ontario, Canada
Alternative Dosing Of Niraparib To Decrease Dose Interruption In First Line Maintenance Treatment For Ovarian Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-07-27
- Last Posted Date
- 2023-11-22
- Lead Sponsor
- Sunnybrook Health Sciences Centre
- Target Recruit Count
- 40
- Registration Number
- NCT05961124
- Locations
- 🇨🇦
Sunnybrook Research Institute, Toronto, Ontario, Canada
Study of ART6043 in Advanced/Metastatic Solid Tumors Patients
- Conditions
- Interventions
- First Posted Date
- 2023-06-12
- Last Posted Date
- 2024-10-29
- Lead Sponsor
- Artios Pharma Ltd
- Target Recruit Count
- 260
- Registration Number
- NCT05898399
- Locations
- 🇺🇸
Jefferson University Hospitals - Kimmel Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸SCRI oncology partners, Nashville, Tennessee, United States
🇺🇸South Texas Accelerated Research Therapeutics (START) - Midwest, Grand Rapids, Michigan, United States
Combination Niraparib and Dostarlimab Therapy for Recurrent or Persistent Uterine Serous Carcinoma
- First Posted Date
- 2023-05-23
- Last Posted Date
- 2024-04-23
- Lead Sponsor
- Casey Cosgrove
- Target Recruit Count
- 35
- Registration Number
- NCT05870761
- Locations
- 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Two-cohort Study of Niraparib and Dostarlimab Plus (Chemo)RadIotherapy in Locally-Advanced Head and Neck Squamous Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2023-03-24
- Last Posted Date
- 2024-02-20
- Target Recruit Count
- 34
- Registration Number
- NCT05784012
- Locations
- 🇪🇸
Complejo Hospitalario de Navarra, Pamplona, Navarra, Spain
🇪🇸Institut Catalá d'Oncologia (ICO) Hospitalet, Hospitalet de Llobregat, Cataluña, Spain
🇪🇸Institut Catalá d'Oncologia (ICO) BADALONA, Badalona, Cataluña, Spain
Study to Evaluate the Safety and Efficacy of TSR-042, Bevacizumab, and Niraparib in Participants With Recurrent Ovarian Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-03-02
- Last Posted Date
- 2023-04-21
- Lead Sponsor
- Tesaro, Inc.
- Target Recruit Count
- 41
- Registration Number
- NCT05751629
- Locations
- 🇺🇸
GSK Investigational Site, Oklahoma City, Oklahoma, United States
Effectiveness and Safety of Niraparib as First-line Maintenance Therapy for Ovarian Cancer: a Real-world Study
- First Posted Date
- 2023-02-21
- Last Posted Date
- 2023-02-21
- Lead Sponsor
- Zhongda Hospital
- Target Recruit Count
- 199
- Registration Number
- NCT05734911
- Locations
- 🇨🇳
Zhongda hospital, Nanjing, China
Niraparib Added to Anti-PD-L1 Antibody Maintenance in SLFN11-positive, Extensive-disease SCLC
- First Posted Date
- 2023-02-08
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- ETOP IBCSG Partners Foundation
- Target Recruit Count
- 44
- Registration Number
- NCT05718323
- Locations
- 🇫🇷
CHU - Angers, Angers, France
🇫🇷Centre Hospitalier d'Avignon, Avignon, France
🇫🇷Caen - CHU, Caen, France
Phase II Trial of the PARP Inhibitor Niraparib and PD-1 Inhibitor Dostarlimab in Patients With Advanced Cancers With Active Progressing Brain Metastases (STARLET)
- First Posted Date
- 2023-01-26
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 120
- Registration Number
- NCT05700721
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Combination Therapy in Cancers With Mutations in DNA Repair Genes
- Conditions
- Interventions
- First Posted Date
- 2023-01-23
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 24
- Registration Number
- NCT05694715
- Locations
- 🇺🇸
University of California, San Francisco, San Francisco, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.